The head of the European office of GV talks about the AI investment cycle and predicts a comeback for Google Glass-style ...
Ever wonder how the bracket is filled out? Or why one team makes it and another doesn't? IndyStar's Zach Osterman got a sneak ...
In patients who had progressed on one prior ARPI, FG3246 plus enzalutamide yielded a median radiographic progression-free survival (rPFS) of 10.1 months and PSA50 response of 40%. Phase I Monotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results